electroCore to Present at the LD Micro Invitational XVI Conference on May 18, 2026
Rhea-AI Summary
electroCore (NASDAQ: ECOR) will present at the LD Micro Invitational XVI conference in Los Angeles on May 18, 2026. Interim President and CFO Joshua Lev will deliver the company presentation at 10:30 am PT and hold one-on-one investor meetings; a webcast is available.
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
Sector peers showed mixed moves, with NMTC down about 4.2% and MYO up about 5.1%. With ECOR up 2.23%, this pattern suggests stock-specific factors rather than a coordinated sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| May 06 | Quarterly earnings | Neutral | -5.9% | Q1 2026 results with 43% net sales growth but ongoing net loss. |
| Apr 30 | Product recognition | Positive | +5.8% | TAC-STIM named national semifinalist in safety innovation challenge. |
| Apr 29 | Earnings date notice | Neutral | +0.0% | Announcement of date and webinar details for Q1 2026 results. |
| Apr 28 | Investor conference | Neutral | +1.3% | Planned presentation and one-on-one meetings at Market Movers Summit. |
| Apr 23 | Media exposure | Positive | +1.0% | Product line featured in documentary on vagus nerve stimulation. |
Recent news has generally seen modest positive price alignment, except for the latest earnings report, which coincided with a negative reaction despite revenue growth.
Over the past few weeks, electroCore has reported Q1 2026 results with strong net sales growth but ongoing losses, preceded by an earnings date announcement. The company highlighted product visibility through a documentary and recognition for TAC-STIM, and has actively participated in investor events such as the Market Movers Summit. Today’s LD Micro conference appearance continues this pattern of outreach and brand-building rather than representing a new financial or clinical inflection point.
Regulatory & Risk Context
An effective S-3 shelf filed on 2025-10-03 registers up to 762,508 shares for resale by existing holders. The company is not issuing new securities under this registration and will not receive proceeds from these stockholder sales, though it bears registration expenses.
Market Pulse Summary
This announcement highlights electroCore’s continued investor outreach, with a presentation and one-on-one meetings at the LD Micro Invitational XVI on May 18, 2026 at 10:30 am PT. It follows recent Q1 2026 results showing strong net sales growth but ongoing losses, plus heightened visibility from product recognition and media coverage. Investors may track how management’s messaging at repeated conferences connects to subsequent financial updates and any changes disclosed in future SEC filings.
AI-generated analysis. Not financial advice.
ROCKAWAY, N.J., May 08, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that it will be participating in the LD Micro Invitational XVI Conference being held at the Luxe Sunset Boulevard hotel in Los Angeles, CA. Joshua Lev, Interim President and CFO, will deliver a presentation and host one-on-one meetings throughout the day.
LD Micro Invitational XVI Conference Details:
Date: Monday, May 18, 2026
Company Presentation: 10:30 am PT
Location: Luxe Sunset Boulevard Hotel, Los Angeles, CA
Webcast: Click for Link
For more information or to attend the conference, click here.
About electroCore, Inc.
electroCore, Inc. is a bioelectronic technology company whose mission is to improve health and quality of life through innovative non-invasive bioelectronic technologies. The Company’s two leading prescription products, gammaCore® non-invasive vagus nerve stimulation (nVNS) and Quell® neurostimulator, treat chronic pain syndromes through non-invasive neuromodulation technology. Additionally, the company commercializes its handheld, and personal use Truvaga™ and TAC-STIM™ nVNS products utilizing bioelectronic technologies to promote general wellness and human performance.
For more information, visit www.electrocore.com.
Contact:
ECOR Investor Relations
(973) 302-9253
investors@electrocore.com
